nVerses Capital’s 2seventy bio TSVT Stock Holding History

nVerses Capital’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,300	Closed	-$10.9K	–	830
2024 Q3	$10.9K	Hold	2,300	–	–	0.01%	880
2024 Q2	$8.86K	Buy	+2,300	New	+$10.4K	0.01%	912

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

nVerses Capital's TSVT Position: Q4 2024 in Review

nVerses Capital sold out of 2seventy bio (TSVT) in Q4 2024, closing a stake of 2,300 shares — an estimated $10.9K sold.

nVerses Capital first reported a position in TSVT in Q2 2024 and held it in 2 quarters. The position peaked at $10.9K in Q3 2024. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2024.

nVerses Capital reported no remaining 2seventy bio position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 2,300 2seventy bio shares in Q4 2024, an estimated $10.9K.
nVerses Capital first reported a position in 2seventy bio in Q2 2024 and held it in 2 quarters.
nVerses Capital's 2seventy bio position peaked at $10.9K in Q3 2024.
116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.